Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. CAR-T therapies are continuing to gain traction in autoimmune disease, with a notable new case.
Also, the FDA has withdrawn approval of GSK’s leucovorin for a rare brain disorder tied to autism, closing out an unusual episode shaped in part by political pressure. Continue to STAT+ to read the full story...
STAT News published a clinical update in Research Highlights on 10 Apr 2026.
The item focuses on STAT+: A new trick for old science, and biotech VCs’ scrambled playbook.
Review the original article for the full source wording and details.